05.11.2015
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler: Successful performance in first nine months of 2015. Moderate third quarter.
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): 9-month figures
Eckert & Ziegler: Successful performance in first nine months of 2015.
Moderate third quarter.
05.11.2015 / 07:45
---------------------------------------------------------------------
Press release
Eckert & Ziegler: Successful performance in first nine months of 2015.
Moderate third quarter.
Berlin, November 5, 2015. Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for isotope technology
applications in medicine, science and industry, achieved sales of EUR 102.7
million in the nine months from January to September 2015.
Compared to the same period in the prior year, sales were up by EUR 10.2
million or 11%. A majority of this amount, EUR 8.3 million, is due to the
more favorable US dollar / euro exchange rate. The acquisition of the
Isotope Products segment in Brazil saw sales climb by EUR 2.3 million.
Organic sales declined slightly by EUR 0.4 million. Thanks to the special
income reported in the second quarter of 2015 from the disposal of the
OctreoPharm Sciences GmbH investment, EBIT improved to EUR 13.8 million for
the first nine months. Profit for the period after taxes and minority
interests also increased sharply to EUR 9.0 million or EUR 1.70 per share.
In the third quarter of 2015, however, business was moderate at the Eckert
& Ziegler Group. With sales of EUR 33.7 million and net income of EUR 1.5
million, the Group generated an average result. For the nine-month period
the results are as follows:
The Isotope Products segment benefited the most from the weak euro, while
also recording a positive acquisition effect. Organic sales declined by EUR
2.8 million due to weak sales in the energy sector and radiocarbon dating.
Two loss-making areas have been identified in the highly successful
segment: the Brazilian business acquired in 2014 and radiocarbon dating. As
a result, EBIT for the entire segment fell by EUR 2.8 million to EUR 9.6
million.
Sales in the Radiation Therapy segment increased by EUR 2.0 million to EUR
21.5 million. Organic sales growth in Afterloaders were strong following
the launch of the new SagiNova(R). Earnings before interest and taxes
(EBIT) fell by EUR 0.5 million to EUR -2.9 million. This already includes
provisions of EUR 1.3 million for restructuring measures and the
consolidation of sites.
The sales of the Radiopharma segment rose by not only the currency effect
but also organically, especially in the equipment division and with the
gallium generators. The segment includes most of the proceeds arising from
the sale of the OctreoPharm investment. As a result, EBIT increased many
times over to EUR 8.7 million.
Price increases meant that the Others segment registered an increase in
sales of EUR 0.6 million to EUR 5.4 million. EBIT increased significantly
by EUR 1.0 million to EUR -1.6 million.
The reduction in net working capital led to a positive cash flow of EUR 2.2
million and the decline in receivables from customers in the Radiation
Therapy segment was the main effect. The disposal of the OctreoPharm
investment led to cash inflow of EUR 5.4 million.
Sales are expected to rise to over EUR 133 million in 2015, while an
improvement in earnings to over EUR 2.00 per share is also targeted. Sales
are expected to increase slightly to between EUR 137 and EUR 140 million in
2016, assuming exchange rates remain stable. Earnings per share are likely
to decline to approximately EUR 1.80 per share in 2016 due to the absence
of positive one-off effects.
The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz315e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str.
10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
---------------------------------------------------------------------
05.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich
End of News DGAP News Service
---------------------------------------------------------------------
408847 05.11.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ